The OPEN framework that the European Medicines Agency started running in 2020 to allow international regulators to participate in its evaluation of EU marketing applications for COVID-19 vaccines and therapeutics has been extended to cover products in other therapeutic areas, including those targeting antimicrobial resistance (AMR).
Medicines that address a high unmet medical need, including some of those designated under the EMA’s PRIME scheme, will also be eligible for assessment under the OPEN framework, as will
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?